

Figure 1




Figure 2




Figure 3

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

3/22




Figure 4




Figure 5

1006009.0320 20/220" 60090001

4/22




Figure 6




Figure 7

TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

5/22




Figure 8




Figure 9

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

6/22




Figure 10

20/220" 60090001




Figure 11.

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH


Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

8/22

Fig. 12



TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH


Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

9/22


Fig.13



1006009-0320

10/22

Fig. 14



10006009-032702

202250 60090000

Lactate acidose patient (H0224)

M10620 (H 0224)




Fig. 15A

Lactate acidose patient (H0224)





Fig. 15B

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH



Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

13/22

Fig. 16






Fig. 18

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

15/22




Fig. 19

202206000001

Significant decrease of mtDNA in PBMC





Fig. 20

17/22

Fig. 21

Copies mtDNA/cell for three individual patients













Fig. 22

19/22

20/230 6090001

Cultured fibroblasts with ddC



Continued culture after ddC removal









Fig. 23

20/22ED 6009000T

Adverse effects of antiretroviral therapy

Percentage of patients changing ART because of adverse effects
(results from the ATHENA-study in the Netherlands)




Fig. 24

DNA-NASBA amplification

denaturing

primer P1 with T7

Reverse transcriptase

T7 RNA polymerase

isolated cellular DNA

**RNase H
primer P1**

Reverse Transcriptase

Reverse Transcriptase

T7 RNA polymerase

primer P2

**anti-sense
RNA**

21/22

Fig. 25

Mitochondria

location of primers for NASBA




Fig. 26